Drug intelligence / Profile preview

1G10

Development stage
Preclinical
Lead developer
Creative Biolabs
Modality
Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

1G10 is an anti-CD86 immunotoxin composed of an anti-CD86 monoclonal antibody (IgG2a) conjugated or fused to Bouganin, a type-I ribosome-inactivating protein (RIP) derived from the leaves of *Bougainvillea spectabilis*. This biologic agent is designed to selectively target and eliminate cells expressing CD86 (B7-2), a cell surface protein often found on certain tumor cells, including those in Hodgkin's disease. Upon binding to CD86, the immunotoxin is internalized via receptor-mediated endocytosis. Once inside the cell, the Bouganin moiety enzymatically depurinates the 28S ribosomal RNA, leading to the irreversible inhibition of protein synthesis and ultimately inducing cell death. 1G10 is primarily utilized as a research compound for investigating targeted therapies against CD86-expressing malignancies.

Other names
anti-CD86-Bouganin immunotoxinanti-CD-86-Bouganin immunotoxinanti-CD 86-Bouganin immunotoxinanti-CD86-Bouganinanti-CD-86-Bouganinanti-CD 86-Bouganin
02

Targets

CD86 (T-lymphocyte activation antigen CD86)Ribosome

Beyond the preview

Go deeper on 1G10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1G10.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call